Banco de Sabadell S.A bought a new stake in ABIOMED, Inc. (NASDAQ:ABMD) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,120 shares of the medical equipment provider’s stock, valued at approximately $1,284,000.
Several other hedge funds have also modified their holdings of the company. Marshall Wace LLP increased its stake in ABIOMED by 252.4% during the 2nd quarter. Marshall Wace LLP now owns 21,569 shares of the medical equipment provider’s stock worth $8,823,000 after buying an additional 15,449 shares during the period. Zacks Investment Management purchased a new stake in ABIOMED during the 2nd quarter worth $1,145,000. Signaturefd LLC increased its stake in ABIOMED by 580.3% during the 2nd quarter. Signaturefd LLC now owns 5,170 shares of the medical equipment provider’s stock worth $2,115,000 after buying an additional 4,410 shares during the period. Paloma Partners Management Co purchased a new stake in ABIOMED during the 2nd quarter worth $716,000. Finally, Cubist Systematic Strategies LLC increased its stake in ABIOMED by 73.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 29,158 shares of the medical equipment provider’s stock worth $11,927,000 after buying an additional 12,358 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.
In other news, Chairman Michael R. Minogue sold 105,000 shares of ABIOMED stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $439.69, for a total value of $46,167,450.00. Following the completion of the transaction, the chairman now directly owns 481,150 shares of the company’s stock, valued at approximately $211,556,843.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO David M. Weber sold 19,282 shares of ABIOMED stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $356.77, for a total transaction of $6,879,239.14. Following the completion of the transaction, the chief operating officer now directly owns 167,124 shares of the company’s stock, valued at $59,624,829.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 175,222 shares of company stock valued at $75,382,784. 3.50% of the stock is owned by company insiders.
Shares of ABMD stock opened at $390.94 on Friday. The firm has a market cap of $17.83 billion, a price-to-earnings ratio of 159.57, a P/E/G ratio of 4.25 and a beta of -0.07. ABIOMED, Inc. has a 1-year low of $155.57 and a 1-year high of $450.93.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, July 26th. The medical equipment provider reported $1.95 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.80 by $1.15. The company had revenue of $180.01 million during the quarter, compared to analyst estimates of $173.87 million. ABIOMED had a net margin of 25.71% and a return on equity of 18.91%. The firm’s revenue for the quarter was up 35.9% compared to the same quarter last year. During the same period last year, the business earned $0.82 EPS. sell-side analysts predict that ABIOMED, Inc. will post 3.46 earnings per share for the current year.
Several research firms recently issued reports on ABMD. BidaskClub downgraded shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $457.00 price objective for the company in a report on Tuesday, July 10th. ValuEngine lowered shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 18th. Piper Jaffray Companies raised their price objective on shares of ABIOMED from $360.00 to $480.00 and gave the stock an “overweight” rating in a report on Friday, June 22nd. Finally, Jefferies Financial Group raised their price objective on shares of ABIOMED to $460.00 and gave the stock a “buy” rating in a report on Tuesday, May 29th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $374.88.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Featured Article: Growth Stocks
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.